Sanofi's Riliprubart Receives Orphan Drug Status In Japan For Rare Nerve Disorder
30/6 07:22
(RTTNews) - French drug major Sanofi S.A. (SNYNF,SNY) announced that the Ministry of Health, Labour and Welfare in Japan has granted orphan drug designation to riliprubart, a monoclonal antibody that selectively inhibits activated C1s in the classical complement pathway for peopl...